Modern Approach to Melanoma Adjuvant Treatment with Anti-PD1 Immune Check Point Inhibitors or BRAF/MEK Targeted Therapy: Multicenter Real-World Report.
Joanna PlaczkeMagdalena RosinskaPaweł SobczukMarcin ZiętekNatasza Kempa-KamińskaBozena Cybulska-StopaGrażyna Kamińska-WinciorekWiesław BalJacek MackiewiczŁukasz GalusManuela Las-JankowskaMichał JankowskiRobert DziuraKamil DrucisAneta BorkowskaTomasz ŚwitajPaweł RogalaKatarzyna KozakAnna KlimczakPaulina Jagodzińska-MuchaAnna Szumera-CiećkiewiczHanna Kosela-PaterczykPiotr RutkowskiPublished in: Cancers (2023)
Melanoma adjuvant therapy with anti-PD1 or DT outside clinical trials appears to be effective and comparable with the results of registration studies. Our data support a de-escalating surgery approach in melanoma treatment.